MicroVision MOVIA lidar gains support on NVIDIA DRIVE AGX platform
LONDON - Angle PLC (AIM:AGL, OTCQX:ANPCY), a prominent firm specializing in liquid biopsy and circulating tumour cell (CTC) diagnostics, is scheduled to unveil its preliminary results for the fiscal year ending December 31, 2024, on Wednesday, May 28, 2025. The announcement will be followed by an analyst meeting at 11:00 am BST the same day, hosted at the offices of FTI Consulting (NYSE:FCN) in London.
The meeting will be broadcast live via a webcast on Angle’s Investor Centre page, with a question-and-answer session reserved exclusively for analysts. Interested parties are encouraged to register in advance and join the webcast shortly before the start time. A recorded version of the event will be available on the company’s website after the meeting concludes.
Angle’s Parsortix® PC1 System, which is FDA cleared and protected by patents, is at the forefront of the company’s offerings. The system allows for comprehensive analysis of CTCs from a simple blood draw, facilitating research, drug development, and clinical oncology applications. The company’s commercial efforts are divided into clinical services provided through its GCLP-compliant laboratories, including assay development and clinical trial testing for pharmaceutical clients, and diagnostic products such as the Parsortix system and related consumables and assays.
With over 100 peer-reviewed studies backing the efficacy of the Parsortix system, Angle PLC has established itself as a leader in the liquid biopsy space. The company’s technology enables whole cell imaging and proteomic analysis, as well as full genomic and transcriptomic molecular analysis, which are critical in the advancement of personalized medicine and cancer treatment.
This upcoming release of preliminary results will offer insights into Angle’s financial performance and operational progress over the past year. The information pertaining to this announcement is sourced from a press release statement provided by RNS, the news service of the London Stock Exchange (LON:LSEG).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.